利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

73 条记录 (耗时 0.021 秒)

    Antimalarial Drug Comprising Alaremycin or Derivative Thereof as Active Ingredient
    1.
    发明申请
    Antimalarial Drug Comprising Alaremycin or Derivative Thereof as Active Ingredient 有权
    包括阿拉霉素或其衍生物的抗疟药物作为活性成分

    公开(公告)号：US20130217913A1

    公开(公告)日：2013-08-22

    申请号：US13883038

    申请日：2011-11-09

    申请人： Masaaki Wachi ,  Shigeharu Sato ,  Tohru Tanaka ,  Kiwamu Takahashi

    发明人： Masaaki Wachi ,  Shigeharu Sato ,  Tohru Tanaka ,  Kiwamu Takahashi

    IPC分类号： A61K31/197 ,  A61K31/16 ,  A61K31/221

    CPC分类号： A61K31/197 ,  A61K9/0019 ,  A61K9/107 ,  A61K9/2018 ,  A61K9/2027 ,  A61K31/16 ,  A61K31/221 ,  Y02A50/411

    摘要： Provided is a preventive and/or therapeutic agent for malaria, comprising, as an active ingredient, 5-acetamido-4-oxo-5-hexenoic acid (Alaremycin) or a derivative thereof. A preventive and/or therapeutic agent for malaria is used which comprises, as an active ingredient, Alaremycin or a derivative thereof represented by formula (I) (wherein R1 represents a hydroxy group, an amino group, or a substituted or unsubstituted straight chain or branched alkoxy group or alkylamino group having 1 to 8 carbons; R2 represents hydrogen, a substituted or unsubstituted straight chain or branched alkyl group having 1 to 8 carbons, or a substituted or unsubstituted aromatic group having 4 to 10 carbons; and R3 represents hydrogen or a methyl group).

    摘要翻译： 本发明提供疟疾的预防和/或治疗剂，其包含作为活性成分的5-乙酰氨基-4-氧代-5-己烯酸（阿拉霉霉素）或其衍生物。 使用疟疾的预防和/或治疗剂，其包含作为活性成分的由式（I）表示的阿拉霉素或其衍生物（其中R 1表示羟基，氨基或取代或未取代的直链或 支链烷氧基或碳原子数为1〜8的烷基氨基; R2表示氢，取代或未取代的碳原子数1〜8的直链或支链烷基或取代或未取代的碳原子数4〜10的芳基，R3表示氢或 甲基）。

    Antimalarial drug comprising alaremycin or derivative thereof as active ingredient
    2.
    发明授权
    Antimalarial drug comprising alaremycin or derivative thereof as active ingredient 有权
    抗疟药包含阿拉霉素或其衍生物作为活性成分

    公开(公告)号：US09295660B2

    公开(公告)日：2016-03-29

    申请号：US13883038

    申请日：2011-11-09

    申请人： Masaaki Wachi ,  Shigeharu Sato ,  Tohru Tanaka ,  Kiwamu Takahashi

    发明人： Masaaki Wachi ,  Shigeharu Sato ,  Tohru Tanaka ,  Kiwamu Takahashi

    IPC分类号： A61K31/197 ,  A61K31/16 ,  A61K31/221 ,  A61K9/00 ,  A61K9/107 ,  A61K9/20

    CPC分类号： A61K31/197 ,  A61K9/0019 ,  A61K9/107 ,  A61K9/2018 ,  A61K9/2027 ,  A61K31/16 ,  A61K31/221 ,  Y02A50/411

    摘要： Provided is a preventive and/or therapeutic agent for malaria, comprising, as an active ingredient, 5-acetamido-4-oxo-5-hexenoic acid (Alaremycin) or a derivative thereof. A preventive and/or therapeutic agent for malaria is used which comprises, as an active ingredient, Alaremycin or a derivative thereof represented by formula (I) (wherein R1 represents a hydroxy group, an amino group, or a substituted or unsubstituted straight chain or branched alkoxy group or alkylamino group having 1 to 8 carbons; R2 represents hydrogen, a substituted or unsubstituted straight chain or branched alkyl group having 1 to 8 carbons, or a substituted or unsubstituted aromatic group having 4 to 10 carbons; and R3 represents hydrogen or a methyl group).

    摘要翻译： 本发明提供疟疾的预防和/或治疗剂，其包含作为活性成分的5-乙酰氨基-4-氧代-5-己烯酸（阿拉霉霉素）或其衍生物。 使用疟疾的预防和/或治疗剂，其包含作为活性成分的由式（I）表示的阿拉霉素或其衍生物（其中R 1表示羟基，氨基或取代或未取代的直链或 支链烷氧基或碳原子数为1〜8的烷基氨基; R2表示氢，取代或未取代的碳原子数1〜8的直链或支链烷基或取代或未取代的碳原子数4〜10的芳基，R3表示氢或 甲基）。

    Cancer heat therapy-enhancing agent
    4.
    发明授权
    Cancer heat therapy-enhancing agent 有权
    癌症热疗增强剂

    公开(公告)号：US09012502B2

    公开(公告)日：2015-04-21

    申请号：US13820303

    申请日：2011-09-12

    申请人： Taku Chibazakura ,  Tohru Tanaka ,  Kiwamu Takahashi ,  Motowo Nakajima ,  Fuminori Abe

    发明人： Taku Chibazakura ,  Tohru Tanaka ,  Kiwamu Takahashi ,  Motowo Nakajima ,  Fuminori Abe

    IPC分类号： A61K31/221 ,  C07C229/22 ,  A61K31/197

    CPC分类号： C07C229/22 ,  A61K31/197

    摘要： Provided is an enhancer for cancer thermotherapy not combined with photodynamic therapy. Cancer treatment not combined with photodynamic therapy is made available by using, as an enhancer for cancer thermotherapy, 5-aminolevulinic acids represented by formula (1): R2R1NCH2COCH2CH2COR3  (1) [wherein R1 and R2 each independently represent a hydrogen atom, an alkyl group, an acyl group, an alkoxycarbonyl group, an aryl group, or an aralkyl group; and R3 represents a hydroxy group, an alkoxy group, an acyloxy group, an alkoxycarbonyloxy group, an aryloxy group, an aralkyloxy group, or an amino group] or a salt thereof.

    摘要翻译： 提供了不与光动力疗法结合的癌症热疗的增强剂。 通过使用作为癌症热疗的增强剂，可以通过使用由式（1）表示的5-氨基乙酰丙酸获得癌症治疗：R2R1NCH2COCH2CH2COR3（1）[其中R1和R2各自独立地表示氢原子，烷基 ，酰基，烷氧基羰基，芳基或芳烷基; R3表示羟基，烷氧基，酰氧基，烷氧基羰基氧基，芳氧基，芳烷氧基或氨基）或其盐。

    Therapeutic agent for allergic rhinitis
    7.
    发明授权
    Therapeutic agent for allergic rhinitis 有权
    过敏性鼻炎治疗剂

    公开(公告)号：US09550073B2

    公开(公告)日：2017-01-24

    申请号：US14125744

    申请日：2012-06-15

    申请人： Tohru Tanaka ,  Katsushi Inoue ,  Kiwamu Takahashi ,  Takuya Ishii ,  Tsutomu Numata ,  Mariko Shibuya ,  Takeshi Suzuki

    发明人： Tohru Tanaka ,  Katsushi Inoue ,  Kiwamu Takahashi ,  Takuya Ishii ,  Tsutomu Numata ,  Mariko Shibuya ,  Takeshi Suzuki

    IPC分类号： A61N5/06 ,  A61K9/06 ,  A61K41/00 ,  A61K9/00

    CPC分类号： A61N5/062 ,  A61K9/0043 ,  A61K9/06 ,  A61K41/0061 ,  F04C2270/0421

    摘要： Provided is a therapeutic agent capable of treating allergic rhinitis in a safe, simple, and noninvasive manner substantially without side effects and physical distress to patients. Provided is a therapeutic agent for allergic rhinitis for 5-aminolevulinic acid-based photodynamic therapy (ALA-PDT) comprising 5-aminolevulinic acid (ALA) or a derivative thereof, or a salt of the 5-aminolevulinic acid or the derivative as an active ingredient, and used in ALA-PDT in which light having a wavelength of 400 nm to 700 nm is irradiated; and particularly provided is a therapeutic agent for allergic rhinitis in a locally applied solution form, a water-soluble ointment-dissolved form, a jelly-dissolved form, or the like. The therapeutic agent does not require the conduct of 5-aminolevulinic acid-based photodynamic diagnosis (ALA-PDD) for detecting a site of protoporphyrin IX (PpIX) accumulation radiating light having a wavelength of 610 nm to 650 nm under irradiation of excitation light having a wavelength of 380 nm to 420 nm before ALA-PDT.

    摘要翻译： 本发明提供能够以安全，简单，无创的方式治疗过敏性鼻炎的治疗剂，其基本上无副作用和对患者的身体伤害。 本发明提供了包含5-氨基乙酰丙酸（ALA）或其衍生物的5-氨基乙酰丙酸类光动力治疗（ALA-PDT）或5-氨基乙酰丙酸或其衍生物的活性成分的过敏性鼻炎的治疗剂 成分，并用于其中照射波长为400nm至700nm的光的ALA-PDT中; 并且特别提供了局部施用的溶液形式的过敏性鼻炎的治疗剂，溶于水的软膏溶解形式，果冻溶解形式等。 治疗剂不需要进行基于5-氨基乙酰丙酸的光动力学诊断（ALA-PDD），用于检测在具有610nm至650nm的波长的照射下发射具有波长为610nm至650nm的光的原卟啉IX（PpIX）积累的位点， 在ALA-PDT之前的波长为380nm至420nm。

    CANCER HEAT THERAPY-ENHANCING AGENT
    8.
    发明申请
    CANCER HEAT THERAPY-ENHANCING AGENT 有权
    癌症治疗增强剂

    公开(公告)号：US20130158293A1

    公开(公告)日：2013-06-20

    申请号：US13820303

    申请日：2011-09-12

    申请人： Taku Chibazakura ,  Tohru Tanaka ,  Kiwamu Takahashi ,  Motowo Nakajima ,  Fuminori Abe

    发明人： Taku Chibazakura ,  Tohru Tanaka ,  Kiwamu Takahashi ,  Motowo Nakajima ,  Fuminori Abe

    IPC分类号： C07C229/22

    CPC分类号： C07C229/22 ,  A61K31/197

    摘要： Provided is an enhancer for cancer thermotherapy not combined with photodynamic therapy. Cancer treatment not combined with photodynamic therapy is made available by using, as an enhancer for cancer thermotherapy, 5-aminolevulinic acids represented by formula (1): R2R1NCH2COCH2CH2COR3   (1) [wherein R1 and R2 each independently represent a hydrogen atom, an alkyl group, an acyl group, an alkoxycarbonyl group, an aryl group, or an aralkyl group; and R3 represents a hydroxy group, an alkoxy group, an acyloxy group, an alkoxycarbonyloxy group, an aryloxy group, an aralkyloxy group, or an amino group] or a salt thereof.

    摘要翻译： 提供了不与光动力疗法结合的癌症热疗的增强剂。 通过使用作为癌症热疗的增强剂，可以通过使用由式（1）表示的5-氨基乙酰丙酸获得癌症治疗：R2R1NCH2COCH2CH2COR3（1）[其中R1和R2各自独立地表示氢原子，烷基 ，酰基，烷氧基羰基，芳基或芳烷基; R3表示羟基，烷氧基，酰氧基，烷氧基羰基氧基，芳氧基，芳烷氧基或氨基）或其盐。

    THERAPEUTIC AGENT FOR ALLERGIC RHINITIS
    10.
    发明申请
    THERAPEUTIC AGENT FOR ALLERGIC RHINITIS 有权
    用于过敏性RHINITIS的治疗剂

    公开(公告)号：US20140188034A1

    公开(公告)日：2014-07-03

    申请号：US14125744

    申请日：2012-06-15

    申请人： Tohru Tanaka ,  Katsushi Inoue ,  Kiwamu Takahashi ,  Takuya Ishii ,  Tsutomu Numata ,  Mariko Shibuya ,  Takeshi Suzuki

    发明人： Tohru Tanaka ,  Katsushi Inoue ,  Kiwamu Takahashi ,  Takuya Ishii ,  Tsutomu Numata ,  Mariko Shibuya ,  Takeshi Suzuki

    IPC分类号： A61K41/00 ,  A61N5/06

    CPC分类号： A61N5/062 ,  A61K9/0043 ,  A61K9/06 ,  A61K41/0061 ,  F04C2270/0421

    摘要： Provided is a therapeutic agent capable of treating allergic rhinitis in a safe, simple, and noninvasive manner substantially without side effects and physical distress to patients. Provided is a therapeutic agent for allergic rhinitis for 5-aminolevulinic acid-based photodynamic therapy (ALA-PDT) comprising 5-aminolevulinic acid (ALA) or a derivative thereof, or a salt of the 5-aminolevulinic acid or the derivative as an active ingredient, and used in ALA-PDT in which light having a wavelength of 400 nm to 700 nm is irradiated; and particularly provided is a therapeutic agent for allergic rhinitis in a locally applied solution form, a water-soluble ointment-dissolved form, a jelly-dissolved form, or the like. The therapeutic agent does not require the conduct of 5-aminolevulinic acid-based photodynamic diagnosis (ALA-PDD) for detecting a site of protoporphyrin IX (PpIX) accumulation radiating light having a wavelength of 610 nm to 650 nm under irradiation of excitation light having a wavelength of 380 nm to 420 nm before ALA-PDT.

    摘要翻译： 本发明提供能够以安全，简单，无创的方式治疗过敏性鼻炎的治疗剂，其基本上无副作用和对患者的身体伤害。 本发明提供了包含5-氨基乙酰丙酸（ALA）或其衍生物的5-氨基乙酰丙酸类光动力治疗（ALA-PDT）或5-氨基乙酰丙酸或其衍生物的活性成分的过敏性鼻炎的治疗剂 成分，并用于其中照射波长为400nm至700nm的光的ALA-PDT中; 并且特别提供了局部施用的溶液形式的过敏性鼻炎的治疗剂，溶于水的软膏溶解形式，果冻溶解形式等。 治疗剂不需要进行基于5-氨基乙酰丙酸的光动力学诊断（ALA-PDD），用于检测在具有610nm至650nm的波长的照射下发射具有波长为610nm至650nm的光的原卟啉IX（PpIX）积累的位点， 在ALA-PDT之前的波长为380nm至420nm。